Track topics on Twitter Track topics that are important to you
Stereotactic Body Radiation Therapy Liver Cancer PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Stereotactic Body Radiation Therapy Liver Cancer articles that have been published worldwide.
We have published hundreds of Stereotactic Body Radiation Therapy Liver Cancer news stories on BioPortfolio along with dozens of Stereotactic Body Radiation Therapy Liver Cancer Clinical Trials and PubMed Articles about Stereotactic Body Radiation Therapy Liver Cancer for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Stereotactic Body Radiation Therapy Liver Cancer Companies in our database. You can also find out about relevant Stereotactic Body Radiation Therapy Liver Cancer Drugs and Medications on this site too.
To evaluate feasibility and efficacy of Stereotactic Body Radiation Therapy (SBRT) for unresectable liver metastasis in oligometastatic patients.
Stereotactic body radiation therapy (SBRT) is an effective therapy for treating liver malignancies. However, little is known about interfractional dose variations to adjacent organs-at-risk (OARs). We examine the effects of interfractional organ movement and setup variation on dose delivered to OARs in patients receiving liver SBRT.
In prostate cancer, it is unknown whether stereotactic body radiation therapy (SBRT) is substituting for other radiation treatments, substituting for surgery, or expanding the pool of patients receiving treatment instead of active surveillance.
This study aimed to generate a functional image of the liver using dual-energy computed tomography (DECT) and a functional-image-based stereotactic body radiation therapy plan to minimize the dose to the volume of the functional liver (V).
The objective of this study was to characterize patients at an increased risk of distant metastasis (DM) following stereotactic body radiation therapy (SBRT) for stage I non-small cell lung cancer (NSCLC).
With increasing use of radiation for hepatocellular carcinoma (HCC) through trans-arterial radioembolization (TARE) and stereotactic body radiation therapy (SBRT), there is concern for increased radiation related complications when using SBRT after TARE. This study compares safety of SBRT following segmental TARE versus trans-arterial chemoembolization (TACE).
Although stereotactic body radiation therapy (SBRT) is an attractive non-invasive approach for liver irradiation, it presents specific challenges associated with respiration-induced liver motion, daily tumor localization due to liver deformation and poor visualization of target with respect to adjacent normal liver in CT. We aim to identify potential hazards and develop a set of mitigation strategies to improve the safety of our liver SBRT program, using failure mode and effect analysis (FMEA).
Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC) is a standard of care for medically inoperable patients. Our aim was to compare Common Terminology Criteria for Adverse Events (CTCAE) thoracic grade 3 or higher adverse events (AEs) of 30 Gy in one fraction (arm 1) vs. 60 Gy in 3 fractions (arm 2).
Response assessment with computed tomography (CT) following stereotactic body radiation therapy (SBRT) for non-small cell lung cancer (NSCLC) is challenging due to a myriad of anatomical changes that can occur after treatment. Diffusion weighted magnetic resonance imaging (DW-MRI) may provide additional data to guide therapy response. The primary objective was to evaluate the effect of SBRT on the mean apparent diffusion coefficient (ADC).
The prognosis of metastatic colorectal cancer (mCRC) is poor. We assessed the feasibility, safety, and efficacy of the anti-programmed cell death 1 fusion protein AMP-224 in combination with low-dose cyclophosphamide and stereotactic body radiation (SBRT) treatment in patients with mCRC refractory to standard chemotherapy.
Tumor aggressiveness and hypoxia are linked to acidosis in the tumor microenvironment (TME). We hypothesized that low pre-treatment serum bicarbonate, potentially correlating with an acidic and hypoxic TME, predicts for poor outcomes after stereotactic body radiation therapy (SBRT) for non-small cell lung cancer (NSCLC).
We sought to characterize temporal trends of radiation oncology resident-reported external beam radiation therapy (EBRT) case experience with respect to various disease sites, including trends in stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) cases.
Stereotactic body radiation therapy (SBRT) has been shown to be effective in treating patients with refractory ventricular tachycardia.
Surgery is the standard of care for early stage non-small cell lung cancer (NSCLC). Stereotactic body radiotherapy (SBRT) is another definitive treatment option for those patients who have not been treated surgically. Comparison of approaches is being explored in NSCLC, but has yet to be compared exclusively in large cell neuroendocrine carcinoma (LCNEC) of the lung. We used the National Cancer Database (NCDB) to conduct such a comparison.
The quality of stereotactic body radiation therapy (SBRT) treatment plans for early stage lung cancer are unknown outside of peer-reviewed publications. Thus, a study was conducted to crowdsource and analyze a variety of lung SBRT treatment plans from around the world.
Use of stereotactic body radiation therapy (SBRT) is increasing in patients with localized prostate cancer, but concerns about early and late gastrointestinal (GI) and genitourinary (GU) toxicity exist after moderately- or extremely hypofractionated radiotherapy schemes. Magnetic resonance-guided radiation therapy (MRgRT) was clinically introduced in 2014, allowing for SBRT delivery with smaller uncertainty margins and permitting daily adaptive planning. A phase II study in patients with localized prostate ...
Immunotherapy has revolutionized the treatment of various types of cancers in recent years. Since the US Food and Drug Administration approval of the anti-cytotoxic T-lymphocyte-associated antigen 4 agent ipilimumab for late-stage melanoma in 2011, results from multiple clinical trials have proven the benefit of immunotherapy in the treatment of other cancers. However, therapeutic resistance to immunotherapy often develops. This has led investigators to combine immunotherapy with stereotactic body radiation...
The standard treatment for patients with early-stage prostate cancer are operation and radiotherapy. Stereotactic body radiation therapy (SBRT) is one of the new radiotherapy methods. The aim of the study was to analyze tumor control of prostate cancer patients treated with SBRT.
To compare the local control and overall survival between stereotactic body radiation therapy (SBRT) and transarterial chemoembolization (TACE) in medium-sized (3-8 cm) hepatocellular carcinoma (HCC).
Retrospective evaluation of stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma (HCC).
Over 80% of pancreatic ductal adenocarcinoma (PDA) patients are diagnosed with non-resectable late-stage disease that lacks effective neoadjuvant therapies. Stereotactic body radiation therapy (SBRT) has shown promise as an emerging neoadjuvant approach for treating PDA, and here, we report that its combination with local interleukin-12 (IL-12) microsphere (MS) immunotherapy results in marked tumor reduction and cures in multiple preclinical mouse models of PDA. Our findings demonstrate an increase of intra...
and purpose: To assess the efficacy and safety of salvage stereotactic body radiotherapy (SBRT) in patients with biopsy-proven local prostate cancer recurrence after radiotherapy.
To interrogate inter-observer variability in gross tumour volume (GTV) and clinical target volume (CTV) delineation specific to the treatment of sacral metastases with spinal stereotactic body radiation therapy (SBRT) and develop CTV consensus contouring recommendations.
Endocrine therapy without radiation therapy is considered appropriate for women age 70 or above with low-risk hormone-positive breast cancer following partial mastectomy. However, some patients may prefer radiation without endocrine therapy, for which there is minimal modern data. We modeled the comparative efficacy of aromatase inhibition alone without radiation versus radiation alone without endocrine therapy.